New Medical Coding Procedures at Clinical CRO ICRC-Weyer

Berlin, Germany, July 20, 2012 --ICRC-Weyer GmbH has announced an enhancement to their medical coding procedures for drug development processes.

Until recently, the company had been utilizing limited licenses for the coding dictionary of the World Health Organization WHO (WHO DD/WHO Drug). WHO DD is an international classification of medicines created by the WHO Programme for International Drug Monitoring and managed by the Uppsala Monitoring Centre. It is used by pharmaceutical companies, clinical trial organizations and drug regulatory authorities for identifying drug names in spontaneous ADR reporting and in clinical trials. There have been major developments in the form of a WHO DD Enhanced (with considerably more fields and data entries) and a WHO Herbal Dictionary, which covers traditional and herbal medicines.

ICRC-Weyer GmbH has now switched to a full, unlimited license of WHO Drug, including the above mentioned Enhanced and Herbal extensions. This enables the company to offer even more versatile and powerful medical coding solutions to a wider range of clients.

All coding at ICRC-Weyer is carried out and controlled within their specialist Medical Data Management department, staffed exclusively by medically trained experts.

Aside from WHO DD, ICRC-Weyer also offers medication coding purely within the WHO ATC classification system, as well as MedDRA and other specialist dictionaries for coding of Adverse Events, medical histories, signs, symptoms, and diseases.

Company Profile:
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.

ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.